| Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. | |
| | |
MedLine Citation:
|
PMID: 23141116 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate whether treatment initiated with an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) for patients with ischemic heart disease, hypertension, or diabetes causes a reduction in hemoglobin (Hb) levels. PATIENTS AND METHODS: This was a retrospective cohort analysis using the computerized database of a large health maintenance organization. Included were all adults with a first purchase of an ACE-I, an ARB, or a calcium channel blocker (CCB) between January 1, 2004, and December 31, 2009, defined as the index date. Measures of Hb levels before and 1 year after the index date were reviewed, and the change was calculated. All the analyses were stratified by pharmaceutical class. The main exposure variables were the proportion of days covered (PDC) by these drugs and the mean enalapril dosage (for enalapril users only). RESULTS: Levels of Hb before and after treatment were available for 14,754 patients taking ACE-Is, 751 taking ARBs, and 3087 taking CCBs. A high PDC was significantly associated with greater yearly reductions in Hb levels compared with a low PDC for CCB use, but was more pronounced for ACE-I and ARB use. A high PDC was also associated with a higher odds of developing anemia in ACE-I users (odds ratio [OR], 1.59; P<.001) and ARB users (OR, 2.21; P=.05). In nonanemic enalapril users, every 10-mg increment in daily dose was associated with an OR of 1.45 for the development of anemia (P<.001). The association remained after excluding nonadherent patients. CONCLUSION: Levels of Hb are reduced during the first year of use of ACE-Is and to a lesser extent with use of ARBs. This association is dose dependent and is not explained by patient adherence. |
| | |
Authors:
|
Eran Leshem-Rubinow; Arie Steinvil; David Zeltser; Shlomo Berliner; Ori Rogowski; Raanan Raz; Gabriel Chodick; Varda Shalev |
Related Documents
:
|
21947376 - Bone density in moroccan women with systemic scleroderma and its relationships with dis... 3970596 - Spontaneous enterogastric reflux gastritis and esophagitis. 6669936 - Duodenogastric reflux after gastric surgery. 11726456 - Gastric residue is not more copious in obese patients. 1853306 - Impaired fibrinolysis and postoperative thromboembolism in orthopedic patients. 21947376 - Bone density in moroccan women with systemic scleroderma and its relationships with dis... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-11-07 |
Journal Detail:
|
Title: Mayo Clinic proceedings. Mayo Clinic Volume: 87 ISSN: 1942-5546 ISO Abbreviation: Mayo Clin. Proc. Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-12-11 Completed Date: 2013-03-12 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0405543 Medline TA: Mayo Clin Proc Country: England |
Other Details:
|
Languages: eng Pagination: 1189-95 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Medicine D, Tel-Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. dr.eranleshem@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Angiotensin Receptor Antagonists / therapeutic use* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Calcium Channel Blockers / therapeutic use Cohort Studies Diabetes Mellitus / drug therapy Dose-Response Relationship, Drug Enalapril / therapeutic use Female Hemoglobins / analysis*, drug effects* Humans Hypertension / drug therapy Logistic Models Male Medication Adherence Middle Aged Myocardial Ischemia / drug therapy Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Calcium Channel Blockers; 0/Hemoglobins; 75847-73-3/Enalapril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effects of the catechol-O-methyltransferase val158met polymorphism on white matter connectivity ...
Next Document: Using social media to improve continuing medical education: a survey of course participants.